Choose a partner to help you succeed

Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The future commercial success of any new inhaled medicine relies largely on the correct combination of formulation and device technology chosen for its delivery. This presentation benefits any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme?

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas

Vectura inhaled formulation, device and development services

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

Vectura Dry Powder Inhaler (DPI) services and capabilities

The expansion will enable the CDMO to widen the nature of inhaled drug development projects it can undertake for customers

Strategies to accelerate inhaled drug development including technology platform selection.

Exploring the many factors which contribute to the success of pMDI, DPI and nebuliser development programmes

The future commercial success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology chosen for its delivery. This presentation will benefit any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme? This session was originally broadcast live as part of CPHI North America 2021

Download this free webcast where Dr Sandy Munro, SVP Pharmaceutical Development, discusses strategies to progress inhaled products quickly to clinical stages of development.

Interested in the critical success factors for an inhaled development programme? Download this article which discusses inhaled delivery platform selection and strategies to accelerate development timelines and reduce risk.

This article discusses how delivery technology can help customers develop existing drugs for inhaled use, as well as highlighting the key challenges and opportunities faced during inhaled product development.